MLH1 and colorectal carcinoma: When analyzing normal tissues, we observed similar risk of CRC recurrence in the advanced stage patients with p16, hMLH1, and MGMT methylation compared with the local stage patients with unmethylation status, with adjusted HRs (95% CI) of 10.85 (4.06–28.96), 9.04 (3.79–21.54), and 12.61 (4.90–32.44), respectively.